Medindia

X

Reportlinker Adds Triple Analysis: Breast Cancer, Lymphoma and Melanoma

Monday, May 23, 2011 General News J E 4
Advertisement

NEW YORK, May 23, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Triple Analysis: Breast Cancer, Lymphoma and Melanoma

http://www.reportlinker.com/p0284781/Triple-Analysis-Breast-Cancer-Lymphoma-and-Melanoma.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

This triple analysis focuses on cancer drug development strategies in Breast Cancer, Lymphoma and Melanoma. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Breast Cancer

The breast cancer report part comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. This report part extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer.

This part is based on the following publication:

Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

Part II: Lymphoma

The lymphoma report part comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 154 investigators, from Ceased to Marketed. This part extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma.

This part is based on the following publication:

A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

Part III: Melanoma

The melanoma report part comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 investigators, from Ceased to Marketed. This part extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma.

This part is based on the following publication:

A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies' pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Breast Cancer

5.1 The Scope of this Report 29

6 Consider the Therapeutic Breast Cancer Target for the Highest Therapeutic Outcome and Return on Investment (207 Drug Targets) 33-376

7 The Rise of New Products: How Mature, Unique and Clinically Validated are the Drug Target Strategies Identified in the Breast Cancer Therapeutic Pipeline? (193 Drug Target Strategies and 405 Drugs) 377-441

8 Compound Strategies at Work: Competitive Benchmarking of Breast Cancer Drugs by Compound Strategy (8 Different Compound Strategies) 442-488

9 Pipeline and Portfolio Planning: Competitive Benchmarking of Breast Cancer Therapeutic Pipeline by Investigator (220 Investigators) 489-891

11 Drug Index 893

12 Company Index 905

Figures: Includes 7 Figures

Tables: Includes 274 Tables

Total Number of Pages: 913

Part II: Lymphoma

5.1 The Scope of this Report 26

6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 30-387

7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs) 388-596

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies) 597-636

9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma) 637-657

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies) 658-938

11 Disclaimer 939

12 Drug Index 940

13 Company Index 948

Figures: Includes 6 Figures

Tables: Includes 222 Tables

Total Number of Pages: 954

Part III: Melanoma

5.1 The Scope of this Report 25

6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (170 Drug Targets) 29-363

7 Emerging New Products to Established Ones: Drug Target Strategies of Melanoma Drugs by their Highest Stage of Development (151 Drug Target Strategies and 218 Melanoma Drugs) 364-538

8 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (8 Compound Strategies) 539-574

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Investigator (138 Companies) 575-766

10 Disclaimer 767

11 Drug Index 768

12 Company Index 773

Figures: Includes 6 Figures

Tables: Includes 196 Tables

Total Number of Pages: 777

To order this report:

Pathology Industry: Triple Analysis: Breast Cancer, Lymphoma and Melanoma

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

CONTACTNicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Triple Analysis: Breast Cancer, ...
S
Reportlinker Adds Triple Analysis: Breast Cancer, ...